5-Aminosalicylic acid-d7 (5-ASA-d7) is intended for use as an internal standard for the quantification of 5-ASA by GC- or LC-MS. 5-ASA is a non-steroidal anti-inflammatory drug (NSAID) and an active metabolite of sulphasalazine , basalazide , and olsalazine .1 It selectively inhibits COX-2 over COX-1 in isolated human whole blood (IC50s = 61 and 410 µM, respectively). 5-ASA inhibits hemoglobin- and hydrogen peroxide-induced lipid peroxidation in a cell-free assay (IC50 = 50 µM).2 It also inhibits the synthesis of leukotriene B4 in isolated human mucosal cells when used at a concentration of 100 µM.3 Formulations containing 5-ASA have been used in the treatment of inflammatory bowel disease (IBD) and ulcerative colitis.
1.Warner, T.D., Giuliano, F., Vojnovic, I., et al.Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysisProc. Natl. Acad. Sci. USA96(13)7563-7568(1999) 2.Beiranvand, M.A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): An anti-ulcer and anti-oxidant drugInflammopharmacology29(5)1279-1290(2021) 3.Schmidt, C., Fels, T., Baumeister, B., et al.The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cellsCurr. Med. Res. Opin.13(7)417-425(1996)